AUTL - CIK 0001730463
Autolus Therapeutics plc trades as AUTL. In its fiscal 2025 annual report the company posted revenue of $75.39M, up 644.9% from the prior year and net income of -$287.53M. This page tracks Autolus Therapeutics plc through 305 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Autolus Therapeutics plc's revenue grew from $1.21M to $75.39M, a compound annual growth rate of 58.2%. Net profit margin expanded from -1035.5% to -381.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
| EFFECT | - | 2026-05-05 |
| EFFECT | - | 2026-05-05 |
| Major company event | 8-K | 2026-04-29 |
| Major company event | 8-K | 2026-04-16 |
The largest companies sharing Autolus Therapeutics plc's SEC industry classification (biological products, (no diagnostic substances)).
Autolus Therapeutics plc reported revenue of $75.39M for fiscal year 2025, an increase of 644.9% year over year.
In its latest fiscal year Autolus Therapeutics plc reported a net loss of $287.53M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.